🔗 Share this article

Given that America undertakes sweeping adjustments to its vaccination recommendations, one figure has emerged unexpectedly: Høeg, an American of Danish descent physician and public health researcher who first made her name by expressing skepticism about COVID-19 vaccines throughout the global health crisis and has focused upon possible fatalities following COVID-19 vaccination in her recent position at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Immunization Program

Health officials were set to announce major changes to the pediatric vaccine schedule recently, synchronizing the US with the Danish vaccine program, it is understood – a major change that would place the US out of alignment with a large portion of the world with no evidence for benefit. The planned update has been pushed back until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is listed to present at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to head the division this calendar year.

A Shift at the FDA

Høeg's temporary position may indicate a closer partnership between the drug and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for discontinuing certain childhood shot schedules in the US so as to align more similar to the Danish model, a society with universal health coverage and a citizenry about the population of the state of Wisconsin.

In her initial public appearances, she has kept her attention on immunizations – traditionally the purview of Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Qualifications

The appointee has no obvious background in medication creation, oversight or administrative roles, which has been typical for former leaders of the CBER. She has been employed at the FDA as a senior adviser to the agency head and CBER since spring.

“She appears not to have the requisite experience” for leading the drug-regulation department, said Jonathan Howard. “She’s never run a clinical trial. She has no expertise in managing a major agency. She is not an expert in pharmaceutical oversight.”

Past directors of CBER would “understand regulatory frameworks and the science of medication creation”, commented Janet Woodcock. “Frankly, she has not acquired the type of experience that former directors who ran CBER have had.”

CDER has an immense portfolio at the FDA, she emphasized.

“Many people just pays attention on the innovative therapies, but the generic drug division clears thousands of generic drugs. There is also a biosimilars program, OTC medication office and more, and each of these must be managed,” she noted. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Additionally, a significant administrative element to the position, which oversees over 5,000 staff members. “It’s a huge administrative position, if you perform it correctly,” Woodcock said.

Official Statement and Controversial Policies

Regarding questions about Dr. Høeg's credentials and whether this selection represents greater collaboration among FDA leaders on vaccines, a spokesperson responded that the “inquiries are based on inaccurate premises”.

“Her resume aligns with the responsibilities of her job,” the spokesperson said, noting the period Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the agency head's new priority voucher program, a disputed expedited therapy clearance system that reportedly troubled her preceding directors. “How are these drugs being chosen for this voucher program? Who is making the choices?” Dr. Howard questioned. “There is a lot of secrecy happening at the FDA right now.”

In general, he said, “the agency appears to be shifting towards more relaxed oversight of pharmaceuticals, except for immunizations.”

Public Track Record on Vaccines

Concerning vaccines, Høeg has a clearer, if problematic, track record, critics have noted. She authored a research paper using unverified public submissions to estimate the frequency of heart inflammation after Covid vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccines are pose a greater threat than they are.

Among her “policy goals” for the current government featured changing regulations for new vaccines and discontinuing “optional” immunizations, she remarked post-election on a online show. At the agency, Høeg has according to sources proposed excluding adolescent males from getting COVID-19 vaccines.

“She’s an thorough true believer who commences with her beliefs and reverse-engineers to accommodate the evidence in a highly disingenuous, untruthful way,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg joined other skeptics, {like|